Laboratory guidelines for monitoring of antimicrobial drugs

Clinical Chemistry

Volumn 44, Issue 5, 1998, Pages 1129-1140

  Hammett Stabler, Catherine A ^a   Johns, Thomas ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CHLORAMPHENICOL; GENTAMICIN; TOBRAMYCIN; VANCOMYCIN;

APLASTIC ANEMIA; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG STABILITY; FLUSHING; GOOD LABORATORY PRACTICE; HUMAN; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHLORAMPHENICOL; DRUG MONITORING; HUMANS; SPECIMEN HANDLING; VANCOMYCIN;

EID: 0031900449     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (166)

1. Robinson JD, Taylor WJ. Interpretation of serum drug concentrations. In: Taylor WJ, Diers Caviness MH, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving TX: Abbott Laboratories; 1986:31-45.
2. Tonkin AL, Bochner F. Therapeutic drug monitoring and patient outcome. A review of the issues. Clin Pharmacokinet 1994;27: 169-74.
3. Gentry CA, Rodvold KA. How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions? Drug Safety 1995;12:359-63.
4. Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit 1990;12:72-8.
5. Moore RD, Lietman PS, Smith CR. Clinical response to aminogly-coside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
6. Horrevorts AM, Mouton JW. Abnormal pharmacokinetics: the need for monitoring. Eur J Clin Microbiol Inf Dis 1993;12(Suppl 1):58-60.
7. Ristuccia AM. Chloramphenicol: clinical pharmacology in pediatrics. Ther Drug Monit 1985;7:159-67.
8. Cantu TG. Vancomycin: current issues and controversies. In: Therapeutic drug monitoring and toxicology. An in-service training and continuing education program. Vol 18. Washington DC: AACC Press, 1997:151-7.
9. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27: 594-8.
10. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Inf Dis 1994;18:533-43.
11. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-50.
12. Lortholary O, Tod M, Cohen Y, Petitjean O. Aminoglycosides. Med Clin N Am 1995;79:761-87.
13. Davies JE. Aminoglycoside-aminocyclitol antibiotics and their modifying enzymes. In: Lorain V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1986:691pp.
14. Stratton CW. Mechanism of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. In: Lorain V, ed. Antibiotics in laboratory Medicine. Baltimore: Williams & Wilkins, 1996:579-603.
15. Belknap S. Aminoglycoside antibiotics. In: Craig CR, Stitzel RE, eds. Modern pharmacology with clinical applications. Boston: Little, Brown and Company, 1997:573-4.
16. Kadurugamuwa JL, Clarke AJ, Beveridge TS. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 1993;175: 5798-805.
17. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorain V, ed. Antibiotics in laboratory medicine, 4th ed. Baltimore: Williams & Wilkins,1996:296-329.
18. Zhanel GG, Hoban DJ, Harding GKM. The post antibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother 1991;25:153-63.
19. Isaksson B, Nilsson L, Maller R, Soren L. Post-antibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988;22:23-33.
20. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
21. Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy 1995;15:297-316.
22. Bates AD, Nahata MC. Once-daily administration of aminoglycosides. Ann Pharmacother 1994;28:757-66.
23. Labovitz E, Levinon ME, Kaye D. Single dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974;6:465-70.
24. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994;13:207-34.
25. Kumin GD. Clinical nephrotoxicity of tobramycin and gentamicin. JAMA 1980;244:1808-10.
26. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986; 80(Suppl 6B):98-104.
27. Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients. J Med 1979; 10:257-66.
28. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990;40:2383-92.
29. Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions. JAMA 1978;240: 2067-9.
30. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:353-7.
31. Brummett RE, Fox KE. Aminoglycoside induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:797-800.
32. Fee WE Jr. Gentamicin and tobramycin: comparison of ototoxicity. Rev Infect Dis 1983;5(Suppl 2):S304.
33. Yee GC, Evans WE. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Pharmacotherapy 1981;1: 55-75.
34. Whelton A. Therapeutic initiatives for the avoidance of aminoglycoside toxicity. J Clin Pharmacol 1985;25:67-81.
35. Konrad F, Wagner R, Neumeister B, Rommel H, Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993;19:215-20.
36. Goodman EL, van Gelder J, Holmes R, Hull AR, Sanford JP. Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrob Agents Chemother 1975;8:434-8.
37. Sarubbi FA, Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978;8(Part 1):612-8.
38. Thompson AH, Campbell KC, Kelman AW. Evaluation of six nomograms using a bayesian parameter estimation program. Ther Drug Monit 1984;6:432-7.
39. Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy 1995;15:201-9.
40. Canis F, Husson MO, Turck D, Vic P, Launay V, Ategbo S, et al. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients J Antimicrob Chemother 1997;39:431-3.
41. Blaser J, Konig C, Simmen HP, Thurnheer U. Antimicrobial practice. Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother 1994;33:341-8.
42. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Inf Dis 1997;24:786-95.
43. Verpooten GA, Giuliano RA, Verbist L, Eestermaus G, deBroe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-7.
44. Gin AS, Ariano RE. Single daily dosing of aminoglycosides [Comment]. Ann Pharmacother 1994;28:1412.
45. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose. An improvement to current practice or a repeat of previous errors? Drugs 1996;52:344-70.
46. Bertino JS, Rotschafer JC. Single daily dosing of aminoglycosides - a concept whose time has not yet come [Editorial]. Clin Inf Dis 1997;24:820-3.
47. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Inf Dis 1997;24:810-5.
48. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Inf Dis 1997;24:796-809.
49. Massey KL, Hendeles L, Neims A. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective. J Pediatr 1986;109:897-901.
50. Amikacin sulfate injection, USP. In: Physicians' desk reference, 51st ed. Montvale, NJ: Medical Economics Company, 1997: 523-5.
51. Garamycin injectable In. Physicians' desk reference, 51st ed. Montvale, NJ: Medical Economics Company, 1997:2502-4.
52. Nebcin, tobramycin sulfate injection, USP. In: Physicians' desk reference, 51st ed. Montvale, NJ: Medical Economics Company, 1997:1518-21.
53. cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
54. Siersbaek-Nielsen K, Molholm-Hansen J, Kampmann J, Kristensen M. Rapid evaluation of creatinine clearance. Lancet 1971;1(Part 2):1133-4.
55. Schwartz GJ, Brion LC, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;343: 571-90.
56. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV, eds. Applied pharmacokinetics, principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:141-7.
57. Mathews SJ. Aminoglycosides. In Schumacher GE, ed. Therapeutic drug monitoring. Norwalk: Appleton & Lange, 1995:237-94.
58. Hendeles L, Iafrate RP, Stillwell PC, Mangos JA. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach. J Pediatr 1987;110:303-10.
59. Gilbert DN, Bennett WM. Use of antimicrobial agents in renal failure. Infect Dis Clin North Am 1989;3:517-31.
60. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharm 1987; 13:228-53.
61. Echeverria P, Siber GR, Paisley J, Smith AL, Smith DH, Jaffe N. Age-dependent dose response to gentamicin. J Pediatr 1975;87: 805-8.
62. Oparaoji EC, Cornwell EE, Hekmat E, Lum Cheong R, Adir JS, Siram S. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993;12:131-4.
63. van der Anwera P. Pharmacokinetic evaluation of single daily dose amikacin. J Antimicrob Chemother 1991;27(Suppl C): 63-7.
64. Gaillard JL, Silly C, LeMasne A, Mahut B, Lacaille F, Cheron G, et al. Cerebrospinal fluid penetration of amikacin in children with community acquired bacterial meningitis. Antimicrob Agents Chemother 1995;39:253-5.
65. Jandreski MA, Garbincius J. Measurement of antimicrobial agents in cerebrospinal fluid using the Abbott TDx analyzer. J Clin Lab Anal 1993;7:263-8.
66. Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurological surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am 1992;3:343-54.
67. Walterspiel JN, Feldman S, Van R, Ravis WR. Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactam and two beta-lactamase inhibitors, cilastatin and heparin. Antimicrob Agents Chemother 1991;35:1875-8.
68. Stabler TV, Ketchum CH, Farringer J. Inactivation of tobramycin by piperacillin as a function of concentration, time, and temperature [Abstract]. Clin Chem 1992;38:1007.
69. Landt M, Smith CH, Hortin GL. Evaluation of evacuated blood collection tubes: effects of three types of polymeric separators on therapeutic drug monitoring specimens. Clin Chem 1993;39: 1712-7.
70. Koch TR, Platoff G. Suitability of collection tubes with separator gels for therapeutic drug monitoring. Ther Drug Monit 1990;12: 277-80.
71. Dasgupta A, Dean R, Saldana S, Kinnaman G, McLawhon RW. Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Volume-and time-dependent reduction in total and free drug concentrations. Am J Clin Pathol 1994;101:456-61.
72. Dasgupta A, Blackwell W, Bard D. Stability of therapeutic drug measurement in specimens collected in Vacutainer plastic blood-collection tubes. Ther Drug Monit 1996;18:306-9.
73. Alcantarilla G, Lozano D. Absorption of some aminoglycoside drugs by barrier gels in sampling tubes. Clin Chem 1996;42: 771.
74. Gentamicin. TDx assay manual. Abbott Park, IL: Abbott Laboratories, 1994.
75. Tobramycin. TDx assay manual. Abbott Park, IL: Abbott Laboratories, 1982.
76. Amikacin. TDx assay manual. Abbott Laboratories, 1995.
77. Fraser CG. Desirable standards of performance for therapeutic drug monitoring. Clin Chem 1987;33:378-89.
78. Department of Health and Human Services. Clinical laboratory improvement amendments of 1988; final rule. Fed Register 1992;57:7001-288.
79. Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997;43:222-7.
80. Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther 1993;20:167-73.
81. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990;19:280-318.
82. Lanao JM, Dominguez-Gil A, Macias JG. The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 1980;18:57-61.
83. Tholl DA, Shikuma LR, Miller TQ, Woodward JM, Cerra FB, Zaske DE. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 1993;21:248-51.
84. Meyers BR, Wilkinson P. Clinical pharmacokinetics of antibacterial drugs in the elderly. Clin Pharmacokinet 1989;17:385-95.
85. Young DS. Effects of drugs on clinical laboratory tests, 4th ed. Washington: AACC Press, 1995:4-23.
86. 1-microglobulin. Pediatr Nephrol 1996;10:645-7.
87. Schentag JJ, Gengo FM, Plaut ME, Danner D, Mangeone A, Jusko WJ. Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother 1979;16:468-74.
88. Ylitalo P, Morsky P, Parviainen MT, Koivula T. Nephrotoxicity of tobramycin. Value of examining various protein and enzyme markers. Methods Find Exp Clin Pharmacol 1991;13:281-7.
89. Adelman RD, Halsted CC, Jordan GW, Russo J. Use of urinary enzyme activities in the early detection of aminoglycoside nephrotoxicity: a study on children and adults receiving gentamicin or netilmicin. Proc West Pharmacol Soc 1981;24:261-4.
90. International Programme on Chemical Safety: Commission of the European Communities. Principle and methods for the assessment of nephrotoxicity associated with exposure to chemicals. Environmental Health Criteria 119. Geneva: World Health Organization, 1991.
91. Elting L, Bodey GP, Rosenbaum B, Fainstein V. Circadian variation in serum amikacin levels. J Clin Pharmacol 1990;30:798-801.
92. Dickson CJ, Schwatzman MS, Bertine JS. Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther 1986;39:325-8.
93. Lucht F, Tigaud S, Esposito G, Congnard J, Gargier MP, Peyramond D, et al. Chronokinetic study of netilmicin in man. Eur J Clin Pharmacol 1990;39:199-201.
94. Fauvelle F, Perrin P, Belfayol L, Bonkari M, Cherrier P, Bosio AM, et al. Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics. Antimicrob Agents Chemother 1994;38:620-3.
95. Sunaga K, Sudoh T, Fujimura A. Lack of diurnal variation in glomerular filtration rates in the elderly. J Clin Pharmacol 1996; 36:203-5.
96. Prins JM, Weverly GJ, van Ketel RJ, Speelman P. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 1997;62:106-11.
97. Holt D, Harvey D, Hurley R. Chloramphenicol toxicity. Adverse Drug React Toxicol Rev 1993;12:83-95.
98. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med 1989;87(Suppl 3N):44N-8N.
99. Kessler DL, Smith AL, Woodrum DE. Chloramphenicol toxicity in a neonate treated with exchange transfusion. J Pediatr 1980; 96:140-1.
100. Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959;261:1318-21.
101. Mulhall A, deLouvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. Br Med J Clin Res Ed 1983;287:1424-7.
102. Glazko AJ. Early adventures in drug metabolism. Chloramphenicol. Ther Drug Monit 1987;9:320-30.
103. Rayner SA, Buckley RJ. Ocular chloramphenicol and aplastic anemia. Is there a link? Drug Saf 1996;14:273-6.
104. Flegg P, Cheong I, Welsby PD. Chloramphenicol. Are concerns about aplastic anaemia justified? Drug Saf 1992;7:167-9.
105. Mulhall A, Berry DJ, deLouvois J. Chloramphenicol in pediatrics: current prescribing practice and the need to monitor. Eur J Pediatr 1988;147:574-8.
106. Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 1984;9:222-38.
107. Chloromycetin sodium succinate. In: Physicians' desk reference, 51st ed. Montvale, NJ: Medical Economics Company, 1997: 1960-1.
108. Roy TE. Studies on absorption of chloramphenicol in normal children in relation to treatment of meningitis. Antibiot Chemother 1952;2:505-9.
109. Yogev R, Williams T. Ventricular fluid levels of chloramphenicol in infants. Antimicrob Agents Chemother 1978;16:7-8.
110. Skopnik H, Heimann G. Pharmacokinetics of antimicrobial drugs in the cerebrospinal fluid. Pediatr Pharmacol 1983;3:313-20.
111. Boer Y, Pijnenburg A. HPLC determination of chloramphenicol degradation in eye drops. Pharm Weekbl Sci 1983;5:95-101.
112. deVries H, Hemelaar PJ, Gevers AC, Beyersbergen van Henegouwen GMJ. Photoreactivity of chloramphenicol in-vitro and in-vivo. Photochem Photobiol 1994;60:249-52.
113. Winsnes R, Borka L, Lonmo A. Decomposition of chloramphenicol in eye drops. Tidsskr Nor Laegeforen 1994;114:2963-5.
114. Dickinson CJ, Reed MD, Stern RC, Aronoff SC, Yamashita TS, Blumer JL. The effect of exocrine pancreatic function on chloramphenicol pharmacokinetics in patients with cystic fibrosis. Pediatr Res 1988;23:388-92.
115. Holt DE, Hurley R, Harvey D. Metabolism of chloramphenicol by glutathione S-transferase in human fetal and neonatal liver. Biol Neonate 1995;65:230-9.
116. Holt DE, Hurley R, Harvey D. A reappraisal of chloramphenicol metabolism: detection and quantification of metabolites in the sera of children. J Antimicrob Chemother 1995;35:115-27.
117. Holt DE. The identification and characterization of chloramphenicol-aldehyde, a new human metabolite of chloramphenicol. Eur J Drug Metab Pharmacokinet 1995;20:35-42.
118. Cravedi JP, Perdu-Durand E, Baradat M, Alary J, Debrauwer L, Bories G. Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct. Chem Res Toxicol 1995;8:642-8.
119. Abon-Khalil NH, Yunis AA, Abon-Khalil S. Stability of chloramphenicol metabolites in human blood and liver as determined by high performance liquid chromatography. Pharmacology 1988; 36:272-8.
120. Yunis AA, Miller AM, Salem Z, Corbett MD, Arimura GK. Nitroso-chloramphenicol: possible mediator in chloramphenicol-induced aplastic anemia. J Lab Clin Med 1980;96:36-46.
121. Bories GF, Cravedi JP. Metabolism of chloramphenicol: a story of nearly 50 years. Drug Metab Rev 1994;26:767-83.
122. Shlaes DM, Marino J, Jacobs MR. Infection caused by vancomycin-resistant Streptococcus sanguis II. Antimicrob Agents Chemother 1984;25:527-8.
123. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 101:284-93.
124. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
125. Luer MS, Hatton J. Vancomycin administration into the cerebrospinal fluid: a review. Ann Pharmacother 1993;27:912-21.
126. Fan Havard P, Nahata MC, Bartkowski MH, Barson WJ, Kosnik EJ. Pharmacokinetics and cerebrospinal fluid concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy 1990;36:103-8.
127. Gump DW. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis 1981;3(sup):S289-92.
128. Swayne R, Pampling A, Newsom SW. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother 1987;19:249-53.
129. Cunha BA. Vancomycin. Med Clin N Am 1995;79:817-31.
130. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 1991;164: 1180-5.
131. O'Sullivan TL, Ruffing MJ, Lamp KC, Warbasse LH, Rybak MJ. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis 1993;168:773-6.
132. Pau AK, Khakoo R. Red neck syndrome with a slow infusion of vancomycin. N Engl J Med 1985;313:756-7.
133. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
134. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Internal Med 1989; 149:1777-81.
135. Salama SE, Rotstein C. Prospective assessment of nephrotoxicity with concomitant aminoglycoside and vancomycin therapy. Can J Hosp Pharm 1993;46:53-9.
136. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974-1981. Antimicrob Agents Chemother 1983;23:138-41.
137. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990;10:378-82.
138. Levy JH, Marty AT. Vancomycin and adverse drug reactions. Crit Care Med 1993;21:1107-8.
139. Goren MP, Baker DK, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989;8:278-82.
140. Wold JS, Turnipseed SA. Toxicology of vancomycin in laboratory animals. Rev Infect Dis 1981;3(Suppl):S224-9.
141. Wood CA, Kohlhepp SJ, Rohnen PW, Houghton DC, Gilbert DN. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 1986;30:20-4.
142. Aronoff GR, Sloan RS, Dinwiddle CB, Giant MD, Fineberg NS, Lugt FC. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 1981;19:306-8.
143. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988;3:376-86.
144. Mellor JA, Kingdom J, Cafferkey M, Keane C. Vancomycin ototoxicity in patients with normal renal function. Br J Audiol 1984;18:179-80.
145. Brummett RE, Fox KE. Vancomycin and erythromycin induced hearing loss in humans. Antimicrob Agents Chemother 1989;33: 791-6.
146. Brummett RE, Fox KE, Jacobs F, Kempton JB, Stokes Z, Richmond AB. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116:61-4.
147. Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985;15: 773-80.
148. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Clin Pharmacokinet 1991;20:463-76.
149. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995;36:279-82.
150. Matzhe GR, Zhanel GG, Gury DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82.
151. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimization of vancomycin therapy. Clin Pharmacokinet 1995;28: 327-42.
152. Catchpole C, Hastings JGM. Measuring pre-and post-dose vancomycin levels-time for a change? J Med Microbiol 1995;45: 309-11.
153. Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 1994;28:1397-9.
154. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Inf Dis 1994;18:544-6.
155. de Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of patients undergoing hemodialysis and hemofiltration. Nephrol Dial Transplant 1989;4:635-9.
156. Barg NL, Supena RB, Fekety R. Persistent staphylococcal bacteremia in an intravenous drug abuser. Antimicrob Agents Chemother 1986;29:209-11.
157. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-gel A. Cost effectiveness analysis of serum vancomycin concentrates monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996;60:332-40.
158. Miles MV, Li L, Lakkis H, Youngblood J, McGinnis P. Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther Drug Monit 1997;19:265-70.
159. Johns TE, Iafrate P, Sproat TT, Palmer S. Antibiotic treatment for infective endocarditis [Letter]. JAMA 1996;275:911.
160. Pou L, Rosell M, Lopez R, Pascual C. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996;18: 149-53.
161. Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA. Falsely elevated serum vancomycin concentrations in hemodialysis pa tients. Am J Kid Dis 1996;27:67-74.
162. Harris CM, Kopecka H, Harris TM. Vancomycin: structure and transformation to CDP-1. J Am Chem Soc 1983;105:6915-22.
163. White LO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DS. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid, and phosphate-buffered saline. J Antimicrob Chemother 1988;22:739-45.
164. Vaughan LM, Poon CY. Stability of ceftazidine and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Ann Pharmacother 1994;28:572-6.
165. Yao JD, Arkin CF, Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: Novel approach to therapy of central venous catheter-related infections. J Parenter Enterai Nutr 1992;16:268-74.
166. Zimmerman AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15:85-91.